$ARGX

AI 分析

生成于 May 11, 2026

AI Score
72/ 100
Hold$ARGX

argenx SE

$ARGXNASDAQHealthcareLarge-Cap

argenx develops antibody-based therapies for autoimmune diseases with lead product Vyvgart for myasthenia gravis.

Market Cap
$32.0B
Revenue (TTM)
$2.5B
+85.0%
Net Income (TTM)
$0.2B
N/A
EPS (TTM)
$3.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$350-$630
Beta
0.72
Dimension Scores
Fundamental
62
Technical
68
Sentiment
78
Risk / Reward
60
Momentum
82
FundTechSentRiskMome
Financial Health
Profitability
67moderate
Growth
85strong
Liquidity
68strong
Solvency
64strong
Efficiency
60moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $ARGX

Free · No credit card required

免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。

探索更多

用 AI 分析任意股票

获取涵盖基本面、技术面、情绪面、风险评估和投资论点的结构化研究报告——约 60 秒完成。